A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer (NCT06774131)
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial cancer (LG-UTUC).
Who can join: Review the eligibility criteria below.
Location: Urology Centers of Alabama — Homewood, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- Urology Centers of Alabama — Homewood, Alabama
- Arizona State Urological Research Institute, LLC ("ASURI") — Chandler, Arizona
- East Valley Urology Center of Arizona — Queen Creek, Arizona
- University of Arkansas for Medical Sciences — Arkansas City, Arkansas
- Michael G Oefelein Clinical Trials — Bakersfield, California
- UC Irvine Health. Chao Family Comprehensive Cancer Center — Orange, California
- Bioresearch Partner - Aventura — Aventura, Florida
- University of Florida Health (UF Health), Cancer Center — Gainesville, Florida
- Bioresearch Partner - Hialeah Hospital — Hialeah, Florida
- D&H National Research Centers - Cancer Research Center, LLC — Margate, Florida
- Urology Center of Iowa Research — Clive, Iowa
- The Urology Center, P.C. — Omaha, Nebraska
- Montefiore Medical Center - Bronx — The Bronx, New York
- University of Cincinnati Medical Center (UCMC) — Cincinnati, Ohio
- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
- Urologic Specialists of Oklahoma — Tulsa, Oklahoma
- Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
- Low county Urology Clinics — North Charleston, South Carolina
- Amarillo Urology Research — Amarillo, Texas
- UPNT Research Institute, LLC — Arlington, Texas
- Texas Urology Specialists-Austin — Austin, Texas
- Renovatio Clinical - The Woodlands Research Center — The Woodlands, Texas
- University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
📞 Contact the Study Coordinator
Phone: (346) 573-2671
Email: renee.sumlin@urogen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Upper Urinary Tract Urothelial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.